NASDAQ:VYGR - Voyager Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $18.27 +0.05 (+0.27 %) (As of 09/25/2018 04:00 PM ET)Previous Close$18.22Today's Range$17.95 - $18.4352-Week Range$11.54 - $31.91Volume381,400 shsAverage Volume419,128 shsMarket Capitalization$590.66 millionP/E Ratio-6.93Dividend YieldN/ABeta2.89 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease. Its preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program, for tauopathies, including Alzheimer's disease, PSP, and FTD; and VY-NAV01 for severe chronic pain. The company has strategic collaboration agreement with AbbVie Inc.; Sanofi Genzyme; the University of Massachusetts; and MRI Interventions, Inc. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. Receive VYGR News and Ratings via Email Sign-up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolNASDAQ:VYGR CUSIPN/A Webwww.voyagertherapeutics.com Phone857-259-5340 Debt Debt-to-Equity RatioN/A Current Ratio6.88 Quick Ratio6.88 Price-To-Earnings Trailing P/E Ratio-6.93 Forward P/E Ratio-5.73 P/E GrowthN/A Sales & Book Value Annual Sales$10.14 million Price / Sales58.45 Cash FlowN/A Price / CashN/A Book Value$4.26 per share Price / Book4.29 Profitability EPS (Most Recent Fiscal Year)($2.64) Net Income$-70,690,000.00 Net Margins-731.88% Return on Equity-80.68% Return on Assets-41.59% Miscellaneous Employees88 Outstanding Shares32,440,000Market Cap$590.66 million Voyager Therapeutics (NASDAQ:VYGR) Frequently Asked Questions What is Voyager Therapeutics' stock symbol? Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR." How were Voyager Therapeutics' earnings last quarter? Voyager Therapeutics Inc (NASDAQ:VYGR) issued its quarterly earnings data on Tuesday, August, 7th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.13. The company had revenue of $2.58 million for the quarter, compared to analyst estimates of $3 million. Voyager Therapeutics had a negative return on equity of 80.68% and a negative net margin of 731.88%. View Voyager Therapeutics' Earnings History. When is Voyager Therapeutics' next earnings date? Voyager Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Voyager Therapeutics. What price target have analysts set for VYGR? 10 analysts have issued 12 month price objectives for Voyager Therapeutics' shares. Their forecasts range from $27.00 to $40.00. On average, they anticipate Voyager Therapeutics' stock price to reach $31.60 in the next year. This suggests a possible upside of 73.0% from the stock's current price. View Analyst Price Targets for Voyager Therapeutics. What is the consensus analysts' recommendation for Voyager Therapeutics? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Voyager Therapeutics. What are Wall Street analysts saying about Voyager Therapeutics stock? Here are some recent quotes from research analysts about Voyager Therapeutics stock: 1. According to Zacks Investment Research, "Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (8/11/2018) 2. BTIG Research analysts commented, "Before mkt open on Thursday, Voyager released their 1Q18 financial results and update. Management reconfirmed that the first patient in the Phase 2-3 Parkinson’s (PD) studies could be dosed during mid-2018, and further confirmed that posterior delivery will be the preferred approach. The decision to use posterior delivery was based upon improved safety, surgical time, and coverage of the putamen – with first data from the posterior study being presented later in 2Q18. The posterior study dataset will focus on patients with 6-months of follow-up, which will be a small group of patients, as the 8 th patient in the posterior study was recently dosed. We reiterate our Buy rating and $32 PT as we remain positive on the PD effort." (5/13/2018) 3. Canaccord Genuity analysts commented, "We note, however, that the IND acceptance is a key step that allows VYGR to start its pivotal Phase 2-3 trial program per plan in 2Q18. VYGR has several potential catalysts coming up over the course of 2018 (see Table 1 on page 2 for details). Specifically, in our view, longer-term Phase 1b data (readouts over 2018) could favorably support the continued development of VY-AADC in advanced PD, and we are reiterating our BUY ahead of the availability of these data." (1/23/2018) Who are some of Voyager Therapeutics' key competitors? Some companies that are related to Voyager Therapeutics include Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), Denali Therapeutics (DNLI), Solid Biosciences (SLDB), Atara Biotherapeutics (ATRA), Rubius Therapeutics (RUBY), Sangamo Therapeutics (SGMO), Editas Medicine (EDIT), Audentes Therapeutics (BOLD), DBV TECHNOLOGIE/S (DBVT), Iovance Biotherapeutics (IOVA), Cellectis (CLLS) and Avrobio (AVRO). Who are Voyager Therapeutics' key executives? Voyager Therapeutics' management team includes the folowing people: Mr. Matthew P. Ottmer, Chief Operating Officer (Age 47)Dr. Steven M. Paul, Exec. Science Advisor & Director (Age 67)Mr. G. Andre Turenne, CEO, Pres & DirectorDr. Krystof Bankiewicz M.D., Ph.D., FounderDr. Guangping Gao Ph.D., Founder Who are Voyager Therapeutics' major shareholders? Voyager Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include TRV GP Iii LLC (24.42%), BB Biotech AG (7.84%), FMR LLC (7.19%), BlackRock Inc. (5.71%), Wells Fargo & Company MN (1.39%) and Laurion Capital Management LP (1.10%). Company insiders that own Voyager Therapeutics stock include Bernard Ravina, Dinah PhD Sah, Glenn Pierce, James A Geraghty and Jane Henderson. View Institutional Ownership Trends for Voyager Therapeutics. Which institutional investors are selling Voyager Therapeutics stock? VYGR stock was sold by a variety of institutional investors in the last quarter, including TRV GP Iii LLC, FMR LLC, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Dynamic Technology Lab Private Ltd and Victory Capital Management Inc.. Company insiders that have sold Voyager Therapeutics company stock in the last year include Bernard Ravina, Dinah PhD Sah and Jane Henderson. View Insider Buying and Selling for Voyager Therapeutics. Which institutional investors are buying Voyager Therapeutics stock? VYGR stock was purchased by a variety of institutional investors in the last quarter, including BB Biotech AG, BlackRock Inc., Trustees of Princeton University, Northern Trust Corp, Laurion Capital Management LP, Wells Fargo & Company MN, Alps Advisors Inc. and Credit Agricole S A. Company insiders that have bought Voyager Therapeutics stock in the last two years include Glenn Pierce and James A Geraghty. View Insider Buying and Selling for Voyager Therapeutics. How do I buy shares of Voyager Therapeutics? Shares of VYGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Voyager Therapeutics' stock price today? One share of VYGR stock can currently be purchased for approximately $18.27. How big of a company is Voyager Therapeutics? Voyager Therapeutics has a market capitalization of $590.66 million and generates $10.14 million in revenue each year. The company earns $-70,690,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. Voyager Therapeutics employs 88 workers across the globe. What is Voyager Therapeutics' official website? The official website for Voyager Therapeutics is http://www.voyagertherapeutics.com. How can I contact Voyager Therapeutics? Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-5340 or via email at [email protected] MarketBeat Community Rating for Voyager Therapeutics (NASDAQ VYGR)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 238 (Vote Outperform)Underperform Votes: 186 (Vote Underperform)Total Votes: 424MarketBeat's community ratings are surveys of what our community members think about Voyager Therapeutics and other stocks. Vote "Outperform" if you believe VYGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VYGR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/25/2018 by MarketBeat.com StaffFeatured Article: What is a closed-end mutual fund (CEF)?